Meeting
2024 ASCO Annual Meeting
Safety and efficacy of durvalumab plus carboplatin and etoposide for patients with previously untreated extensive-stage small-cell lung cancer (ES-SCLC) with a poor performance status: The results from phase II single-arm study (NEJ045A study).
Authors
Yu Saida
Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
Yu Saida , Tetsuhiko Asao , Satoshi Watanabe , Akira Kisohara , Kazuma Kishi , Ryo Morita , Taku Nakagawa , Yoko Tsukita , Naoki Furuya , Taichi Miyawaki , Nobuhisa Ishikawa , Tadaaki Yamada , Takahiro Tanaka , Satoshi Morita , Toshiaki Kikuchi , Makoto Maemondo , Kunihiko Kobayashi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
jRCTs031200319
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 8101)
DOI
10.1200/JCO.2024.42.16_suppl.8101
Abstract #
8101
Poster Bd #
363
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
A phase 1b study of ensartinib in combination with platinum-based chemotherapy and bevacizumab in ALK-positive non-small cell lung cancer (NSCLC).
First Author: Kyle Concannon
Poster
2024 ASCO Annual Meeting
DAREON-8: A phase I, open-label, dose escalation/expansion trial of the DLL3-targeting T-cell engager, BI 764532, combined with first-line (1L) standard of care (platinum, etoposide, and anti-PD-L1 antibody) in patients (pts) with extensive-stage small cell lung carcinoma (ES-SCLC).
First Author: Solange Peters
Poster
2023 ASCO Annual Meeting
Safety and efficacy of QL1706 plus carboplatin/etoposide (EC) as first-line (1L) treatment for extensive-stage small-cell lung cancer (ES-SCLC): The results from a phase II single-arm study.
First Author: Yun Fan
Poster
2023 ASCO Annual Meeting
First line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2): Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.
First Author: Michael Thomas Mark